Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Mathieu, Chantal; Wych, Julie; Hendriks, Emile AEJ; Van Ryckeghem, Lisa; Tree, Timothy; Chmura, Piotr; Möller, Christopher; Casteels, Kristina; Danne, Thomas; Reschke, Felix; Šmigoc Schweiger, Darja; Battelino, Tadej; Johannesen, Jesper; Rami-Merhar, Birgit; Pieber, Thomas; De Block, Christophe; Evans, Mark; Hilbrands, Robert; Bosi, Emanuele; Willemsen, Ruben H; Basu, Supriyo; Pulkkinen, Mari Anne; Knip, Mikael; Cnop, Miriam; Nitsche, Almut; Schulte, Anke M; Niemöller, Elisabeth; Peakman, Mark; Wilhelm-Benartzi, Charlotte; Gillespie, David; Overbergh, Lut; Mander, Adrian Paul; Marcovecchio, Maria Loredana; INNODIA

doi:doi/10.1016/S0140-6736(25)01674-5

Citer

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Article révisé par les pairs

Titre:	Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
Auteur:	Mathieu, Chantal; Wych, Julie; Hendriks, Emile AEJ; Van Ryckeghem, Lisa; Tree, Timothy; Chmura, Piotr; Möller, Christopher; Casteels, Kristina; Danne, Thomas; Reschke, Felix; Šmigoc Schweiger, Darja; Battelino, Tadej; Johannesen, Jesper; Rami-Merhar, Birgit; Pieber, Thomas; De Block, Christophe; Evans, Mark; Hilbrands, Robert; Bosi, Emanuele; Willemsen, Ruben H; Basu, Supriyo; Pulkkinen, Mari Anne; Knip, Mikael; Cnop, Miriam; Nitsche, Almut; Schulte, Anke M; Niemöller, Elisabeth; Peakman, Mark; Wilhelm-Benartzi, Charlotte; Gillespie, David; Overbergh, Lut; Mander, Adrian Paul; Marcovecchio, Maria Loredana; INNODIA,
Informations sur la publication:	Lancet, 406, 10510, page (1375-1388)
Statut de publication:	Publié, 2025-09-01
Sujet CREF:	Sciences bio-médicales et agricoles
	Diabétologie
	Endocrinologie
	Métabolisme
MeSH keywords:	Humans
	Adolescent
	Antilymphocyte Serum -- administration & dosage -- adverse effects
	Double-Blind Method
	Diabetes Mellitus, Type 1 -- drug therapy
	Male
	Female
	Child
	Young Adult
	Adult
	Child, Preschool
	Immunosuppressive Agents -- administration & dosage
	Dose-Response Relationship, Drug
	Treatment Outcome
Langue:	Anglais
Identificateurs:	urn:issn:0140-6736
	info:doi/10.1016/S0140-6736(25)01674-5
	info:pii/S0140-6736(25)01674-5
	info:pmid/40976248

Référencement	Visibilité	Pérennité	Facilité
Les publications encodées constituent la bibliographie académique de l'Université.	Les documents déposés sont indexés par les moteurs de recherche (Google Scholar,…).	Les documents déposés en open-access sont archivés au sein du réseau de préservation SAFE-PLN (www.safepln.org).	Les listes de publications sont compatibles avec le CV-ULB, le FNRS et accessibles sur le web.

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Documents en relation

DI-fusion